Coronavirus (COVID-19) information: Due to the outbreak of coronavirus (COVID-19), this study is not recruiting any new patients at the moment. Speak to your doctor or nurse if you would like to know more about this. If you are taking part in this study, your medical team will continue to support you and provide information. If you have pancreatic cancer and have any questions about how coronavirus might affect you, you can speak to our specialist nurses on our free Support Line, or visit the NHS website.
A phase 2 trial looking at two different chemotherapy treatments before surgery for pancreatic cancer
Research title: A study looking at two different neo-adjuvant chemotherapy treatments for people with pancreatic cancer who may be suitable for surgery.
Why is this trial being carried out?
Surgery is the most effective treatment for pancreatic cancer. Research has suggested that having chemotherapy before surgery may shrink the cancer. This may mean there is a better chance of removing it. The NICE guidelines recommend that chemotherapy before surgery should be looked at in clinical trials.
Chemotherapy that you have before surgery is called neo-adjuvant chemotherapy. The PRIMUS-002 trial will look at two neo-adjuvant chemotherapy treatments:
If you take part in the PRIMUS-002 trial, your oncologist will decide which of the two chemotherapy treatments you will have. Your medical team will talk to you about which treatment you will have and what this treatment will involve.
This phase 2 trial is linked to the Precision Panc study. This means that you will need to join the Precision Panc study and provide blood and tissues samples in order to take part in the PRIMUS-002 trial. You may have already provided these samples during your diagnosis and treatment. Researchers will use these samples to look at the genes in your cancer. They want to see if differences in the genes affect how well the treatments work.
The PRIMUS-002 trial may be suitable for you if you:
- are taking part in the Precision Panc study
- have operable (resectable) or borderline resectable pancreatic cancer
- are well enough to take part – you will have tests to check this
- are able to have a metal stent put into your bile duct if you have jaundice.
The PRIMUS-002 trial may not be suitable for you if you:
- have pancreatic cancer that has spread to another part of your body (advanced or metastatic pancreatic cancer)
- have had other cancers – apart from some types of skin cancer and cervical cancer
- have already had chemotherapy, or chemotherapy together with radiotherapy (chemoradiotherapy)
- currently have an infection, including herpes or chickenpox
- have a heart condition that isn’t controlled with treatment
- have had major surgery in the month before starting the trial
- have severe diarrhoea, and medication is not controlling this
- have neuropathy (tingling in your fingers and toes) that affects how you can use your fingers and toes.
There may be other reasons for not being able to take part in a trial. It is important to speak to your doctor about whether this trial might be suitable for you.
Recruitment start date: Currently suspended
Recruitment end date: Currently suspended
The PRIMUS-002 trial will be carried out in:
- Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN
Dr Derek Grose
You can contact the trial centre by email on: email@example.com
Or by telephone on: 0141 330 2718
How to join a trial
Please speak to your consultant about whether this trial is suitable for you.
If you have any questions about pancreatic cancer you can speak to one of our specialist nurses on our Support Line.
How to find out more
For further information about this trial please visit the UK Clinical Trials Gateway website.
Published: March 2019
Review date: March 2021